pSivida Announces Top-Line Results from Investigator-Sponsored Phase II Study of Medidur for Uveitis to Be Reported Next Week

pSivida Corp.

, a leader in the development of sustained release drug delivery products for treating eye diseases, announced that top line results from an investigator-sponsored, Phase II study of pSivida's Medidur for uveitis will be presented at the 33rd Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) meeting to be held July 10-14 in Vienna, Austria. Dr. Glenn J. Jaffe, Robert Machemer Professor of Ophthalmology at Duke University School of Medicine in Durham, NC, who is conducting this study, will make the presentation. He also serves as principal investigator in pSivida's first pivotal Phase III trial for Medidur for posterior uveitis, which is currently underway. The American Society of Retina Specialists, a non-profit corporation, provides a scientific forum to promote the advancement of vitreoretinal diseases and surgery to its more than 2,600 members in the United States, Puerto Rico and 59 countries.